Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy — BLAD-RAD01

Urothelial Bladder Cancer Clinical Trial

Official title:
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial

Status Recruiting

Clinical Trial Summary

This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy plus standard of care improves overall survival as compared to standard of care in patients with limited metastatic urothelial bladder cancer and without progression following the initial phase of first-line systemic therapy. Each patient will be followed during 4 years from the date of randomization.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04428554
Study type	Interventional
Source	Institut Claudius Regaud
Contact	Jonathan KHALIFA
Phone	05 31 15 54 01
Email	khalifa.jonathan@iuct-oncopole.fr
Status	Recruiting
Phase	Phase 2
Start date	June 30, 2020
Completion date	July 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02527434` - Study of Tremelimumab in Patients With Advanced Solid Tumors	Phase 2
Recruiting	`NCT06335667` - mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer	N/A
Terminated	`NCT04197986` - Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations	Phase 3
Recruiting	`NCT05080998` - CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients
Suspended	`NCT04779151` - Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	Phase 2